| Ident. | Authors (with country if any) | Title |
|---|
| 000C82 |
Jacquie Chirgwin [Australie] ; ZHUOXIN SUN [États-Unis] ; Ian Smith [Royaume-Uni] ; Karen N. Price [États-Unis] ; Beat Thürlimann [Suisse] ; Bent Ejlertsen [Danemark] ; Hervé Bonnefoi [France] ; Meredith M. Regan [États-Unis] ; Aron Goldhirsch [Italie, Suisse] ; Alan S. Coates [Australie] | The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause |
| 003889 |
Alan S. Coates [Allemagne, Suisse, Australie, États-Unis, Danemark, France, Belgique, Italie, Hongrie, Royaume-Uni, Pologne] ; Aparna Keshaviah ; Beat Thurlimann ; Henning Mouridsen ; Louis Mauriac ; John F. Forbes ; Robert Paridaens ; Monica Castiglione-Gertsch ; Richard D. Gelber ; Marco Colleoni ; Istvdn Ldng ; Lucia Del Mastro ; Ian Smith ; Jacquie Chirgwin ; Jean-Marie Nogaret ; Tadeusz Pienkowski ; Andrew Wardley ; Erik H. Jakobsen ; Karen N. Price | Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer : Update of study BIG 1-98 |
| 003A23 |
Henning Mouridsen [Danemark, États-Unis, Suisse, Australie, France, Belgique, Italie, Royaume-Uni] ; Aparna Keshaviah ; Alan S. Coates ; Manuela Rabaglio ; Monica Castiglione-Gertsch ; ZHUOXIN SUN ; Beat Thurlimann ; Louis Mauriac ; John F. Forbes ; Robert Paridaens ; Richard D. Gelber ; Marco Colleoni ; Ian Smith ; Karen N. Price ; Aron Goldhirsch | Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen : Safety Analysis of BIG 1-98 Trial |
